

MitraClip™  
Transcatheter Edge-to-Edge Repair

EXPERIENCE  
MATTERS



Information contained herein for DISTRIBUTION  
in Europe, Middle East, and Africa ONLY.





## MITRACLIP™ TEER TOGETHER WE EMPOWER EACH OTHER TO TREAT PATIENTS WITH OUTSTANDING PERFORMANCE IN TEER

With Abbott's help, you've **transformed more than 200,000<sup>1</sup> lives** with MitraClip™ TEER, including Luca's and that number is growing every day.

“MitraClip™ changed my life.  
I've achieved the objective I'd set for myself –  
200 km of *The Camino del Norte* on foot.”  
Luca, SMR patient treated with MitraClip™ in 2009

\*This testimonial relates an account of an individual's response to the treatment. This patient's account is genuine, typical, and documented. However, it does not provide any indication, guide, warranty, or guarantee as to the response other persons may have to the treatment. Responses to the treatment discusses can and do vary and are specific to the individual patient.

## TOGETHER WE CAN TRANSFORM MORE PATIENT LIVES, HELPING THEM TO LIVE A BETTER LIFE



MitraClip™ TEER provides the most **significant improvement in QOL** and functional class.

Information contained herein for DISTRIBUTION in Europe, Middle East, and Africa ONLY.


# MITRACLIP™ TEER TOGETHER WE DELIVER UNPARALLELED OUTCOMES WITH UNCOMPROMISING PERFORMANCE IN TEER

The **standard of care** in TMVr, with **20+ years** of innovation and experience.

MitraClip™ TEER Implant and System have been designed with intention to **maximize MR reduction** in a safe procedure and has driven the **shortest device time** to date.\*



The shortest device time to date in TEER




Highest and most durable MR reduction reported to date

\*Median device time of 35 minutes with the MitraClip™ TEER G4 system from the EXPAND G4 study. †1-year outcomes with the MitraClip™ TEER G4 system from the EXPAND G4 study.

## MitraClip™ TEER#4-20

MR Severity at Discharge or 30 Days\*



## OUR COMBINED EXPERIENCE IS DRIVING NEW STANDARDS IN TEER

\*Discharge rate was used if 30-day data not available. Mack et. al. did not report MR≤1+, rate assumed from Mitra.FR, Sorajja TVT 2017. †All study years based on end of enrollment (trials), analysis period (TVT, STS registries), or publication year. Note: Data not from head-to-head studies. Data are provided for informational purposes only.

Information contained herein for DISTRIBUTION in Europe, Middle East, and Africa ONLY.



## MITRACLIP™ TEER EXPERIENCE MATTERS



**20+**  
years of evidence in TEER



**200,000+<sup>1</sup>**  
patients worldwide



**80,000+<sup>1</sup>**  
patients studied

## THANK YOU FOR THE PARTNERSHIP IN THIS JOURNEY



Information contained herein for DISTRIBUTION in Europe, Middle East, and Africa ONLY.



Visit CONNEXT by Advanced Heart Therapies to find out more about MitraClip™ TEER and access **next-level cardiovascular educational content** tailored just for you

EU, European Union; FR, France; HR, high risk; KCCQ-OS, Kansas City Cardiomyopathy Questionnaire Overall Score; min, minute; MR, mitral regurgitation; NHR, non-high risk; NYHA, New York Heart Association; QOL, quality of life; RCT, randomized controlled trial; SMR, secondary mitral regurgitation; STS, Society of Thoracic Surgeons; TEER, transcatheter edge-to-edge repair; TMVr, transcatheter mitral valve repair; TVT, transcatheter valve therapy.

**REFERENCES:** **1.** Data on file at Abbott. **2.** von Bardeleben R.S. Contemporary clinical and echocardiographic outcomes of 1000+ patients treated with MitraClip™ G4: Results from the EXPAND G4 post-approval study. Data Presented at TCT 2022. **3.** von Bardeleben R.S., et al. 1-year outcomes with fourth-generation mitral valve transcatheter edge-to-edge repair from the EXPAND G4 study. *JACC Cardiovasc Interv.* 2023;16:2600–2610. doi: 10.1016/j.jcin.2023.09.029. **4.** Feldman T. Final results of the EVEREST II randomized controlled trial of percutaneous and surgical reduction of mitral regurgitation. Presented at ACC 2014. **5.** Kar S. MitraClip™ in high-risk patients – final 5-year results of the EVEREST II high risk registry. Data presented at ACC 2014. **6.** Feldman T. The EVEREST II REALISM continued access non-high risk study: Mid- and long-term follow-up in surgical candidates. Presented at ESC 2017. **7.** Maisano F, et al. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. *J Am Coll Cardiol.* 2013;62:1052–1061. doi: 10.1016/j.jacc.2013.02.094. **8.** EVEREST II REALISM Continued access study high risk group. Final report Feb 2018. Data on file at Abbott. **9.** Sorajja P., et al. Outcomes with transcatheter mitral valve repair in the United States: An STS/ACC TVT registry report. *J Am Coll Cardiol.* 2017;70:2315–2327. doi: 10.1016/j.jacc.2017.09.015. **10.** Stone G. COAPT: A randomized trial of transcatheter mitral valve leaflet approximation in patients with heart failure and secondary mitral regurgitation. Presented at TCT 2018. **11.** Obadia J-F., et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. *N Engl J Med.* 2018;379:2297–2306. doi: 10.1056/NEJMoa1805374. **12.** Mack M, et al. Transcatheter mitral valve therapy in the United States. *J Am Coll Cardiol.* 2021;78:2326–2353. doi: 10.1016/j.jacc.2021.07.058. **13.** Kar S., et al. Core-lab adjudicated contemporary clinical outcomes at 1 year with MitraClip™ (NTR/XTR) system from global EXPAND study presented at TCT 2020. **14.** von Bardeleben R.S., et al. Contemporary clinical and echocardiographic outcomes of 1000+ patients treated with MitraClip™ G4: Results from the EXPAND G4 post-approval study presented at TCT 2022. **15.** Izumo M., Contemporary 3-year outcomes from 500 patients treated with MitraClip: Results from the Japan post-marketing surveillance study. Presented at PCR Tokyo Valves, Feb 2023. **16.** EII RCT final report 2014, Table 33, paired results out to 5-years. **17.** REALISM HR 2018 final report on file. **18.** von Bardeleben R.S., et al. 1-year outcomes with fourth-generation mitral valve transcatheter edge-to-edge repair from the EXPAND G4 study. *JACC Cardiovasc Interv.* 2023;16:2600–2610. doi: 10.1016/j.jcin.2023.09.029. **19.** Lim D.S., 5-year durability results of transcatheter mitral valve repair. Presented at ACC 2018. **20.** Stone G. 5-year follow-up after transcatheter repair of secondary mitral regurgitation. Presented at ACC 2023.

**CAUTION:** Product(s) intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at vascular.eifu.abbott or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events. Information contained herein for DISTRIBUTION in Europe, Middle East, and Africa ONLY. Always check the regulatory status of the device in your region. Illustrations are artist's representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.

Abbott Vascular International BVBA  
Park Lane, Culliganlaan 2B, 1831 Diegem, Belgium, Tel: 32 2 714 14 11  
™ indicates a trademark of the Abbott Group of Companies.  
www.my-connext.com  
©2024 Abbott. All rights reserved. 9-EH-1-14849-01 01-2024

